Tempus AI TEM operates at the intersection of clinical genomics and AI-driven insights. Its testing and data products are gaining traction with providers and biopharma partners. With revenue up ...

Tempus AI (TEM) just secured FDA 510(k) clearance for its new AI driven diagnostic tools, a milestone that could shift how investors think about the company’s role in precision oncology. See our ...

In the Seventies (I first saw her at the Albert Hall in 1972) she toured with a band but for a couple of decades now she’s worked solely with pianist and musical director Russell Walden, a gentle ...

Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry ...

Tempus AI specializes in developing artificial intelligence solutions to improve patient outcomes in various healthcare fields. Ark Invest reduced the Tempus AI position in the ARK Innovation ETF.

Prior to the start of this week, Tempus AI (NASDAQ: TEM) stock had locked in a 161% gain since the start of the year -- an impressive performance for the healthcare company that's pioneering ...

Almost Famous star Patrick Fugit has opened up about his decision to move away from Hollywood, opting instead for life in rural Texas. Fugit, 42, made his screen acting debut with Cameron Crowe’s hit ...

25 years after 'Almost Famous' hit theaters, Patrick Fugit recalls talking about video games with Brad Pitt when they screen tested for the movie together J. Vespa/WireImage; Michael Crabtree - PA ...

"I was super nervous, because he was a movie star and I wanted to do a good job and all that. But he was very cool," Fugit says of meeting Pitt Pitt passed on the Almost Famous role of a guitarist for ...

Almost Famous star Patrick Fugit tells PEOPLE about screen testing for the movie with Brad Pitt as he discusses the movie's 25th anniversary "I was super nervous, because he was a movie star and I ...

Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...